康方生物:依沃西1L肺癌获批在即 多癌种3期快速推进

华福证券
02 Apr

投资要点:依沃西:1L 肺癌有望25H1 获批,已开展5 个其他癌种的3 期临床依沃西从2024 年至今取得多个关键进展:1)联合化疗治疗EGFR-TKI耐药非鳞状NSCLC 的适应症已获得NMPA 批准上市,被纳入2024 年国家医保目录;2)依沃西单药一线治疗PD-L1 阳性NSCLC(vs K 药)适应症上市申请已获得优先审评,有望2025H1 获批上市。非头对头数据显示,依沃西单药治疗PD...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10